Theragenics to distribute Oncuras brachytherapy products

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon
Theragenics has signed a non-exclusive agreement with Oncura to distribute its brachytherapy-related products in North America.

The one-year agreement is effective May 1 and provides for additional one-year terms upon mutual agreement of the parties, said the Buford, Ga.-based Theragenics.

Oncura, a unit of GE Healthcare, manufactures, markets and sells the iodine-125 based OncoSeed used in prostate cancer treatments.